Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morrow

Showing results (261-270 of 10,456) with videos related to

Pageof 1,046
Sort By:
IRB|September 5, 2008
Missing subjectsDuke Morrow
Cancer Research|December 19, 2013
It is not always necessary to do axillary dissection for T1 and T2 breast cancer--pointMonica Morrow
Managed Care (Langhorne, Pa.)|November 25, 2011
Benefits of ticagrelor debated as antiplatelet class approaches generic marketThomas Morrow
Managed Care (Langhorne, Pa.)|April 5, 2012
Rules for evaluating biosimilars put applicants through hoopsThomas Morrow
JAMA|January 3, 1996
A 47-year-old woman with ductal carcinoma in situM Morrow
Cancer|October 1, 1995
The natural history of ductal carcinoma in situ. Implications for clinical decision makingM Morrow
Managed Care (Langhorne, Pa.)|August 12, 2014
Myalept approved for treatment of disorders marked by loss of body fatThomas Morrow
Managed Care (Langhorne, Pa.)|August 14, 2013
Do comparable efficacy & convenient dosing justify Procysbi's extremely high price?Thomas Morrow
Managed Care (Langhorne, Pa.)|September 12, 2013
New sentinel lymph node mapping tool spots cancer with futuristic effectivenessThomas Morrow
Breast (Edinburgh, Scotland)|August 8, 2015
Progress in the surgical management of breast cancer: Present and futureMonica Morrow
Pageof 1,046

Showing results (261-270 of 10,456) with videos related to

Sort By:
Pageof 1,046
IRB|September 5, 2008
Missing subjectsDuke Morrow
Cancer Research|December 19, 2013
It is not always necessary to do axillary dissection for T1 and T2 breast cancer--pointMonica Morrow
Managed Care (Langhorne, Pa.)|November 25, 2011
Benefits of ticagrelor debated as antiplatelet class approaches generic marketThomas Morrow
Managed Care (Langhorne, Pa.)|April 5, 2012
Rules for evaluating biosimilars put applicants through hoopsThomas Morrow
JAMA|January 3, 1996
A 47-year-old woman with ductal carcinoma in situM Morrow
Cancer|October 1, 1995
The natural history of ductal carcinoma in situ. Implications for clinical decision makingM Morrow
Managed Care (Langhorne, Pa.)|August 12, 2014
Myalept approved for treatment of disorders marked by loss of body fatThomas Morrow
Managed Care (Langhorne, Pa.)|August 14, 2013
Do comparable efficacy & convenient dosing justify Procysbi's extremely high price?Thomas Morrow
Managed Care (Langhorne, Pa.)|September 12, 2013
New sentinel lymph node mapping tool spots cancer with futuristic effectivenessThomas Morrow
Breast (Edinburgh, Scotland)|August 8, 2015
Progress in the surgical management of breast cancer: Present and futureMonica Morrow
Pageof 1,046